Amgen (AMGN) Cash from Investing Activities (2009 - 2026)

Amgen's Cash from Investing Activities history runs 18 years deep, the most recent figure standing at -$716.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 60.18% year-over-year to -$716.0 million; the TTM figure through Mar 2026 stood at -$2.2 billion (down 73.35% YoY), while the FY2025 annual figure was -$1.9 billion, down 85.76% from the prior year.
• Cash from Investing Activities was -$716.0 million for Q1 2026 at Amgen, down from -$693.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $1.4 billion in Q1 2023 to a low of -$27.1 billion in Q4 2023.
• Historically, Cash from Investing Activities has averaged -$2.1 billion across 5 years, with a median of -$389.0 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 1410.0% in 2022, then soared 1323.42% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$3.5 billion in 2022, then sank by 679.99% to -$27.1 billion in 2023, then jumped by 98.52% to -$402.0 million in 2024, then plunged by 72.39% to -$693.0 million in 2025, then dropped by 3.32% to -$716.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$716.0 million (Q1 2026), -$693.0 million (Q4 2025), and -$414.0 million (Q3 2025), per Business Quant data.